loading page

Preclinical characterization of alginate-Poly-L-Lysine encapsulated HepaRG for extracorporeal liver supply
  • +4
  • Mattia Pasqua,
  • Ulysse Pereira,
  • Claire de Lartigue,
  • Jonathan Nicolas,
  • Pascale Vigneron,
  • Quentin Dermigny,
  • Cecile Legallais
Mattia Pasqua
Universite de Technologie de Compiegne
Author Profile
Ulysse Pereira
Universite de Technologie de Compiegne
Author Profile
Claire de Lartigue
Universite de Technologie de Compiegne
Author Profile
Jonathan Nicolas
Universite de Technologie de Compiegne
Author Profile
Pascale Vigneron
Universite de Technologie de Compiegne
Author Profile
Quentin Dermigny
Universite de Technologie de Compiegne
Author Profile
Cecile Legallais
Université de Technologie de Compiègne
Author Profile

Peer review status:UNDER REVIEW

23 May 2020Submitted to Biotechnology and Bioengineering
23 May 2020Assigned to Editor
23 May 2020Submission Checks Completed
05 Jul 2020Reviewer(s) Assigned

Abstract

We recently demonstrated that HepaRG cells encapsulated into 1.5% alginate beads are capable of self-assembling into spheroids. They adequately differentiate into hepatocyte-like cells, with hepatic features observed at day 14 post-encapsulation required for external bioartificial liver applications. Preliminary investigations performed within a bioreactor under shear stress conditions and using a culture medium mimicking acute liver failure (ALF) highlighted the need to reinforce beads with a polymer coating. We demonstrated in a first step that a Poly-L-Lysine coating improved the mechanical stability, without altering the metabolic activities necessary for bioartificial liver applications (such as ammonia and lactate elimination). In a second step, we tested the optimized biomass in a newly-designed perfused dynamic bioreactor (PDB), in the presence of the medium model for pathological plasma for 6 hours. Performances of the biomass were enhanced as compared to the steady configuration, demonstrating its efficacy in decreasing the typical toxins of ALF. This type of bioreactor is easy to scale up as it relies on the number of micro-encapsulated cells, and could provide an adequate hepatic biomass for liver supply. Its design allows it to be integrated into a hybrid artificial/bioartificial liver setup for further clinical studies regarding its impact on ALF animal models.